Back to Results
Medical Oncologist; Assistant Professor, TUSM
Department + Services
Clinical Focus Areas
Acute leukemia, malignant hematology, myelodysplastic syndromes, myeloproliferative disorders
Research Focus Areas
Hematologic malignancies, with a focus on improving decision-making and cancer care delivery for adults with lymphomas and leukemias
Seeing Patients In
|Programs + Specialties
|Training + Education
Albert Einstein College of Medicine; Internal Medicine: University of Pennsylvania, 2011
Hematology/Oncology: University of Pennsylvania Abramson Cancer Center, 2014
||Internal Medicine, Medical Oncology, Hematology
||View Accepted Insurances at Tufts MC + Floating Hospital
Tufts Medical Center
860 Washington St.
South Building, Floor 7
Boston, MA 02111
Phone #: 617-636-6227
Fax #: 617-636-8538
Kumar AJ, Hexner E, Frey N, Luger S, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer E, Levine B, June C, Porter D, & Goldstein S. “A Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation.” Biology of Blood & Marrow Transplantation, 19: 1094-1101, 2013. PMID 23635453.
Kumar AJ, Vassilev P, Loren AW, Luger SM, Reshef R, Gill S, Smith J, Goldstein SC, Hexner E, Stadtmauer EA, Porter D, Frey N. “Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.” American Journal of Hematology. 4: 426-9, 2012. PMID 26820493.
Kumar AJ, Gimotty P, Gelfand J, Buck G, Rowe J, Goldstone A, Fielding A, Marks D, Litzow M, Paietta E, Lazarus H, Tallman M, Luger S, & Loren AW. “Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients.” American Journal of Hematology: 2016 Nov;91(11):1107-1112. PMID 27468137; PMCID PMC5073003.
Kumar AJ, Kim S, Hemmer MT, et al. “Graft versus host disease in recipients of male unrelated donor compared to parous female sibling donor transplants.” Blood Adv. 2018 May 8;2(9):1022-1031. PMID 29739773. PMCID PMC5941995.
Parsons SK, Kelly MJ, Cohen JT, Catellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. “Early-stage hodgkin lymphoma in the modern era: simulation modeling to delineate long-term patient outcomes.” British J Haematol. 2018 Jul;182(2):212-221. PMID 29707774. PMCID PMC6055753.
Kumar AJ. “Drawing the Line of Ineligibility.” Blood 2018 Jun 21; 131(25): 2739-2740. PMID 29930149.
Parsons SK, Kumar AJ. “Adolescent and Young Adult Cancer Care: Financial Hardship and Continued Uncertainty.” Pediatric Blood and Cancer. 2018. In press.
Dr. Kumar is a board certified hematologist and oncologist. She completed her undergraduate degree at the Massachusetts Institute of Technology. She earned her Medical Doctorate at the Albert Einstein College of Medicine. She then went on to complete her residency in internal medicine and fellowship in hematology/oncology at the University of Pennsylvania, where she also earned a master’s of science in clinical epidemiology. Dr. Kumar specializes in care of adults with hematologic malignancies as well as in survivorship care for adolescents and adults who have been treated for cancer.
American Society of Hematology
Eastern Cooperative Oncology Group
Cancer and Aging Research Group
Center for International Blood and Marrow Transplant Research
I am health services researcher within hematologic malignancies, with a focus on improving decision-making and cancer care delivery for adults with lymphomas and leukemias. My work includes identifying treatment patterns, healthcare utilization, and survival outcomes for patients treated in both academic and community-based settings. This is through the use of population databases, administrative claims, and integrated community datasets. I am also working with a large team on developing a simulation model to determine risk of late effects in lymphoma after treatment with chemotherapy and/or radiation with the goal of individualizing decision-making at diagnosis to optimize survival while minimizing late effects.